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ORIGINAL RESEARCH
Objectives: The aim of this longitudinal, open-label, comparative, multicenter study was to
assess cognitive function in hypertensive patients receiving mid-term treatment with
lercanidipine.
Methods: Hypertensive patients aged 40 years or older were treated with lercanidipine (10 mg
daily) after 7–10 days washout period. The duration of the study was 6 months. Blood pressure
(BP) was measured every 4 weeks (JNC 6th report). In patients with inadequate BP control,
doxazosin was added and up-titrated. At baseline and after 6 months of treatment, cognitive
function was evaluated using the Spanish validated version of the Mini-Mental State
Examination (MMSE) and the Trail Making Test (TMT).
Results: In the study population of 467 patients, BP decreased from 154.4/95.3 mmHg at
baseline to 134.8/80.7 mmHg at 6 months. At the end of the study, 98% of patients were
receiving lercanidipine, 20% an angiotensin-converting enzyme inhibitor, and 6% doxazosin.
Adequate BP control was obtained in 68% of patients. The mean (standard deviation) MMSE
scores improved from 32.35 (2.59) to 33.25 (2.36) (p<0.0001). Patients with good BP control
scored significantly better than those with inadequate BP control (p<0.05), which was already
observed at the first month.
Conclusions: The third-generation calcium channel antagonist, lercanidipine, improved
cognitive function after 6 months of treatment especially in patients with good BP control,
suggesting that improvements in cognitive function may be associated with a decrease in BP.
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Introduction
High blood pressure is a major risk factor for stroke and ischemic heart disease. The
fact that hypertension increases with age may account for the expected increase in
the incidence of acute cerebrovascular events and coronary artery disease in Western
countries. On the other hand, dementia (Skoog et al 1996) and cognitive impairment
(Kilander et al 1998) have been increasingly related to hypertension. It has been
shown that hypertension precedes vascular dementia and Alzheimer-like dementia
(Forette et al 1998). In this respect, some studies provided evidence that, in contrast
to previous findings, antihypertensive treatment can prevent or delay the onset of
dementia (Forette et al 2002). However, there is some controversy about the current
information on whether the type of antihypertensive treatment used has an influence
on the level of improvement in the cognitive function. The recently published Study
on Cognition and Prognosis in the Elderly (SCOPE) (Lithell et al 2003) did not find
any differences between a treatment based on an angiotensin-II receptor antagonist
and an antihypertensive treatment that did not involve this drug class. To date, no
studies have been published directly investigating cognitive function with third-
generation calcium channel antagonists.
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Lercanidipine is a vasoselective dihydropyridine calcium
channel antagonist that causes systemic vasodilation by
blocking the influx of calcium ions through L-type calcium
channels in cell membranes. It is a highly lipophilic drug
that exhibits a slower onset and longer duration of action
than other calcium channel antagonists. Furthermore,
lercanidipine may have antiatherogenic activity unrelated
to its antihypertensive effect. In two large, non-blind, non-
comparative studies involving approximately 16 000 patients
with mild to moderate hypertension, systolic blood pressure
(SBP) and diastolic BP (DBP) were significantly reduced
after 12 weeks’ treatment with lercanidipine 10–20 mg/day
(Bang et al 2003). The purpose of this study was to assess
cognitive function by means of two tests evaluating
cognitive disorders and psychomotor speed in patients with
essential hypertension receiving mid-term treatment with
lercanidipine, a third-generation calcium channel blocker.
Patients and methods
This was a longitudinal, open-label, comparative,
multicenter study, which was designed to determine the
effect of antihypertensive treatment with lercanidipine on
cognitive function. Eligible patients were treated with
lercanidipine with the possibility of adding an angiotensin-
converting enzyme (ACE) inhibitor and doxazosin when
adequate BP control with lercanidipine monotherapy was
not achieved. The duration of the study was 6 months and
was conducted in the primary care setting.
Male and female patients aged ≥40 years with newly
diagnosed essential hypertension (SBP ≥140 mmHg, DBP
≥90 mmHg in non-diabetic subjects; SBP ≥135 mmHg, DBP
≥85 mmHg in patients with diabetes mellitus) or need to
change the current medication for those subjects treated with
antihypertensive drugs as monotherapy who were not
managed according to guidelines of the 6th report of the
Joint National Committee (National High Blood Pressure
Education Program 1997) were eligible. The following
exclusion criteria were applied: current treatment with
lercanidipine and/or an ACE inhibitor and/or doxazosin;
presence of secondary hypertension, symptomatic heart
disease, organic cognitive impairment, serum creatinine
concentration >1.7 mg/dL, venous insufficiency of the lower
limbs, inability to complete the Mini-Mental State
Examination (MMSE) (baseline MMSE score <27 for
patients aged ≥60 years, and <24 for patients aged ≥61
years), as well as any contraindication for prescribing
treatment with lercanidipine as considered by the
investigator. Pregnant women, nursing mothers, or women
of childbearing potential not using adequate methods of
contraception were also excluded. Written informed consent
was obtained from all participants.
Readings of SBP and DBP were taken with a
sphygmomanometer with the patient seated in a chair with
back supported, after 10 minutes of quiet rest. A visit blood
pressure was the average of two separate measurements
taken by the examining physician (a third measurement was
obtained when there was a difference of 5 mmHg between
the two readings). Adequate control of blood pressure was
defined as SBP ≤140 mmHg and DBP ≤90 mmHg for non-
diabetic patients, and SBP ≤135 mmHg and DBP ≤85 mmHg
for patients with diabetes (National High Blood Pressure
Education Program 1997).
The study medication was dispensed at the baseline visit.
The daily dose was one tablet of lercanidipine (Zanidip
®,
Recordati España, San Sebastián de los Reyes, Madrid),
10 mg, taken with a glass of water immediately after
breakfast. In previously treated hypertensive patients, a
washout period of 7–10 days was required. Patients were
assessed at baseline and at 4, 8, 12, 16, 20, and 24 weeks
after commencement of treatment with lercanidipine. At
each visit, blood pressure and heart rate were measured,
and compliance with treatment was checked. During the
clinic visits, study therapy could be uptitrated by adding a
second antihypertensive drug (ACE inhibitor) and third
antihypertensive drug (doxazosin) if blood pressure was still
not controlled. The ACE inhibitor treatment was left to the
treating physician. The same dose of lercanidipine was given
throughout the 6-month study period. Treatment with
doxazosin  was  started  with  a  single  daily  dose  of  2 mg,
taken at night, followed by increases up to 8 or 16 mg daily
if adequate control of BP was not achieved. Routine
laboratory tests, including complete blood cell count, serum
glucose concentration, liver and renal function tests, lipid
profile, and ionogram were performed at baseline (visit 1)
and after 6 months of treatment (visit 7). The body mass
index (BMI) was also calculated. Obese patients were those
with BMI ≥30 kg/m
2.
Cognitive function was assessed at baseline (visit 1) and
at the end of the study (visit 7) using the MMSE and the
Trail Making Test A (TMT-A) (Reltan 1959). The MMSE
is used as a screening tool for the detection of cognitive
disorders (Folstein et al 1975) and the TMT-A evaluates
attention, concentration and psychomotor function. The
MMSE is a widely used, well-validated screening tool for
evaluation of cognitive impairment (Kukull et al 1994). It
briefly measures orientation to time and place, immediateVascular Health and Risk Management 2006:2(4) 493
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recall, short-term verbal memory, calculation, language, and
construct ability. In this study, the Spanish validated version
of MMSE was used (Lobo et al 1999). It should be noted
that the Spanish version of MMSE has a score of between 0
and 35. The TMT-A involves drawing a line to link a series
of numbered dots that have been distributed over a sheet of
paper. The score is obtained by measuring the time (in
seconds) it takes the patient to complete the test and the
number of mistakes made. In order to prevent test/re-test
improvement in MMSE and TMT-A, patients were not told
about correctness (incorrectness) or the interpretation of
scores obtained either before or after testing. In the two tests,
patients were questioned by a trained investigator.
Statistical analysis
Categorical data are expressed as absolute numbers and
percentages and continuous data as mean and standard
deviation (SD). In order to study differences in the
quantitative variables over time as well as progression, or
between group differences, the analysis of variance
(ANOVA) for repeated or independent measurements was
used. Categorical data were analyzed with the chi-square
(χ2) test for independent samples or the McNemar’s test for
paired samples. The relationship between results of the
MMSE and the patient’s age and BMI was assessed with
the Pearson product-moment correlation coefficient (r).
Statistical significance was set at p<0.05. The Statistical
Analysis Systems (SAS Institute, Cary, NC, USA) statistical
software package for Windows was used to analyze the data.
Results
Of the 544 patients who agreed to take part in the study, 77
(14.1%) were excluded for the following reasons: MMSE
score at baseline lower than that required for entry (n=66),
lack of compliance with treatment (n=10), and violation of
the BP inclusion criterion (n=1). Therefore, the study
population included 467 patients (67% males) aged between
42 and 79 years (mean 61.1±8.3 years). Fifty-six percent of
patients were older than 60 years of age.
At the end of the study, 98.8% of patients were under
treatment with lercanidipine, 20% had an ACE inhibitor
added, and 6.1% doxazosin. Seventy-eight percent of
patients received lercanidipine as monotherapy and 20%
combined with the ACE inhibitor and doxazosin.
The mean BP of 154.4/95.3 mmHg at baseline decreased
to 134/80.7 mmHg after 6 months of treatment. SBP
decreased by 11.8% and DBP by 15.2%. These differences
were statistically significant (p<0.01). Changes of BP
readings during the study period are shown in Table 1. The
overall percentage of patients with adequate control of BP
was 68.3%. The percentage of patients with adequate control
of BP was 82.7% in those younger than 60 years of age
compared with 54.9% in patients with 60 years or more.
However, BP readings at baseline were significantly higher
in the older age group (161.3/94.5 mmHg vs 145.3/
96.2 mmHg, p<0.01). On the other hand, the percentage of
patients with adequate BP control was significantly higher
in non-obese patients (BMI <30 kg/m
2) than in obese
subjects (BMI ≥30 kg/m
2) (70.3% vs 51.1%, p<0.01), as
well as in patients treated with lercanidipine monotherapy
than in those given lercanidipine in combination with an
ACE inhibitor and doxazosin (74.7% vs 49.2%, p<0.01).
Significant variations in pulse rate and laboratory
parameters between values at visits 1 and 7 were not
observed.
The mean MMSE score at the beginning of the study
(baseline) was 32.35±2.59 points, which increased
significantly at the final visit with a mean score of
33.25±2.36 (p<0.0001). As compared with baseline, a
statistically significant (p<0.0001) decrease in the seconds
Table 1 Changes of blood pressure and heart rate during the 6-month study period
Visits Percentage of patients treated with SBP DBP Heart rate
mmHg
a mmHg
a beats/min
a
Lercanidipine ACE inhibitor Doxazosin
Baseline 0 0 0 154.4 (14.4) 95.3 (6.3) 74.7 (9.1)
15 days 100 0 0 147.4 (12.1) 91.2 (6.3) 75.3 (8.2)
1 month 99 14 0 142.2 (10.7) 87.7 (6.5) 75.2 (8.2)
2 months 98 19 3 139.4 (9.5) 85.2 (6.3) 74.8 (7.9)
3 months 98 20 4 137.9 (9.5) 83.4 (6.1) 74.7 (7.7)
4 months 98 20 6 136.5 (8.8) 82.5 (6.3) 74.6 (7.6)
5 months 98 20 6 135.3 (8.1) 81.6 (5.9) 74.1 (7.4)
6 months 98 20 6 134.8 (8.1) 80.7 (5.5) 74.1 (7.2)
aData as mean and standard deviation (SD).
Abbreviations: ACE, angiotensin-converting enzyme; DBP, diastolic blood pressure; SBP, systolic blood pressureVascular Health and Risk Management 2006:2(4) 494
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required to complete the TMT-A (76.20±58.77 vs
64.14±38.70s) and in the number of mistakes (2.82±2.70
vs 1.79±1.36) recorded at the final visit was also observed.
In addition, there was a statistically significant inverse
correlation between MMSE scores and patient’s age (r =
–0.529, p<0.001), that is, the younger the patient, the better
the MMSE score. In fact, at the end of treatment subjects
younger than 60 years scored significantly higher than those
older than 60 years (34.43±1.37 vs 32.14±2.55, p<0.0001).
No significant correlation was found between MMSE score
and obesity (r = –0.056, p=0.25). On the other hand, there
were no significant differences in the mean MMSE score at
the end of the study regarding the use of lercanidipine as
monotherapy or in combination (33.3±2.41 vs 33.09±2.22).
The ANOVA analysis for the MMSE showed significant
differences in the test scores between patients with adequate
BP control and those in whom adequate control was not
achieved (Table 2). In patients with adequate control of BP,
the final MMSE score was 33.67±2.15 compared with
32.31±2.54 in patients without adequate BP control. In
patients without BP control, MMSE score decreased from
33.25±2.36 at baseline to 32.31±2.54 at the end of the study.
Discussion
Firstly, this study shows that lercanidipine was efficient for
controlling BP in 68% of a population of hypertensive
patients who were either previously uncontrolled or who
were just starting pharmacological therapy. The safety
profile was excellent: at the end of the study, 98% of patients
were still on lercanidipine treatment. Secondly, it has been
observed that lercanidipine has a beneficial effect on the
MMSE-measured cognitive function after 6 months of
treatment. This is especially significant in those subjects
with controlled BP, which suggests that the improvement
of the cognitive function may be associated with a decrease
in BP.
Despite all the campaigns that have been launched in
the last three decades to improve control of hypertension,
this is achieved in only a small proportion of hypertensive
patients. Stroke rate (age-adjusted) has increased slightly
since 1993, the reduction of ischemic heart disease has
slowed down, and heart failure and progressive renal failure
have increased. In the late 1990s, strict BP control did not
even reach 30% of cases, with figures of only 27% in the
United States (American Heart Association 1998), 24% in
France (Chamontin et al 1998), 16% in Canada (Joffres et
al 1997), 6% in the United Kingdom (Colhoun et al 1998),
and 16.3% in Spain (Coca Payeras 1998; Barrios et al 2002).
However, the situation has somewhat improved as a result
of the introduction of newer and safer antihypertensive
medications and to greater awareness of the importance of
adequate BP control among healthcare professionals and
the general population. Unfortunately, adequate BP control
is still to be achieved in more than half of hypertensive
patients.
The present results show that a therapeutic regimen with
a third-generation dihydropyridine, such as lercanidipine,
achieves BP control after 6 months of treatment in 68.3%
of the patients, which is considerably higher than the average
rates obtained with other current antihypertensive regimens.
This is even more remarkable considering that, at the end
of the study, 78% of patients were receiving lercanidipine
as monotherapy, and in this subset of patients, BP control
was achieved in 74.7% of them. We found that BP control
was poorer in obese hypertensive subjects, although
adequate BP control was obtained in 51% of these patients.
Control of BP in obese hypertensive patients is even more
significant if we take into account that long-term weight
Table 2 Results of the Mini-Mental State Examination (MMSE) according to whether adequate control of blood pressure was
achieved
Patients without adequate BP control Patients with adequate BP control
Visit, no. patients MMSE score, mean (SD) Visit, no. patients MMSE score, mean (SD)
Baseline, n=467 33.25 (2.36) Baseline, n=467 33.25 (2.36)
15 days, n=400 33.23 (2.37) 15 days, n=16 33.69 (1.91)
1 month, n=316 33.12 (2.42) 1 month, n=97 33.66 (2.13)
a
2 months, n=236 32.81 (2.59) 2 months, n=174 33.82 (1.89)
b
3 months, n=187 32.63 (2.67) 3 months, n=224 33.74 (1.95)b
4 months, n=172 32.47 (2.70) 4 months, n=238 33.79 (1.92)
b
5 months, n=140 32.43 (2.60) 5 months, n=239 33.66 (2.12)
b
6 months, n=131 32.31 (2.54) 6 months, n=281 33.67 (2.15)b
ap=0.48 and 
bp<0.0001 compared with patients with adequate blood pressure (BP) control.Vascular Health and Risk Management 2006:2(4) 495
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reductions are not achieved in 80% of the cases. It is equally
important to see how BP control is achieved in 82.7% of
patients under 60 years of age, whereas in patients of 60
years or older, BP control was obtained in 54.9% of patients
probably in relation to higher baseline SBP values in this
group.
There is increasing evidence that high blood pressure
can contribute to the development of cognitive function
impairment and the onset of dementia (Launer et al 1995;
Glynn et al 1999; Guo et al 1999). However, there is no
general consensus on the mechanism whereby this occurs.
In an analysis of the Framingham study, it was observed
that a 12- to 15-year follow-up revealed impairment in the
cognitive function in later years in untreated patients with
high SBP and DBP (Farmer et al 1990; Elias et al 1993).
Stratification by age showed a tendency to better cognitive
function in subjects over 75 years of age if they had no
isolated systolic hypertension or diastolic hypertension. The
follow-up was extended to a 20-year observation period that
showed a strong relationship between cognitive dysfunction
and untreated hypertensive subjects compared with the
hypertensive treated group. In the Honolulu study, a 25-
year follow-up further emphasized the association between
middle age systolic BP and cognitive impairment in later
years (Launer et al 1995). This association between elevated
systolic BP levels (and pulse pressure) and impairment in
cognitive function could be anatomically reflected as brain
atrophy (den Heijer et al 2003) and especially with white
matter lesions (de Leeuw et al 2002). Therefore, it seems
logical to believe that reducing BP by providing
antihypertensive therapy may protect against development
or onset of cognitive function impairment and dementia.
In one of the first large studies in which the impact of
antihypertensive treatment on cognitive function was
evaluated, the SHEP study on systolic hypertension in the
elderly, no beneficial or deleterious effect was observed on
cognitive function (Applegate et al 1994). However, the
Syst-Eur study, published subsequently, which also
investigated systolic hypertension in the elderly but had a
different drug regimen, supported the hypothesis that
antihypertensive treatment could be beneficial for cognitive
function (Forette et al 1998).
 Treatment of systolic
hypertension in elderly subjects with no previous dementia
reduced the risk of developing dementia and Alzheimer’s
disease. In another study, the Kungsholmen study (Vitanen
et al 1998) antihypertensive therapy reduced incidence of
later development of dementia. In the Rotterdam study, for
which more than 7000 hypertensive elderly subjects were
included, the risk for dementia, particularly for the vascular
type, was reduced by 30% in those patients who were
receiving antihypertensive treatment (In’t Veld et al 2001).
This reduction was important but not significant, unlike the
differences observed in the Syst-Eur
 and Kungsholmen
studies (Forette et al 1998; Vitanen et al 1998).
Antihypertensive treatment seems to be associated with a
decrease in cerebral white matter lesions especially in the
subcortical and paraventricular regions (Liao et al 1996;
Dufouil et al 2001). These are the regions that appear to be
associated with cognitive function impairment, although the
relationship is unclear. Recently, Paran et al (2003) found
poorer cognitive function in the presence of lower blood
pressure and observed that mild hypertension improves
cognitive function.
The discrepancies found among some of these studies,
regarding the beneficial effect of antihypertensive treatment
on global cognitive function, should be explained by the
designs of different studies, their sample sizes, the different
tests and methods used to assess cognitive function and to
define dementia, and by the fact that cognitive function has
been a secondary endpoint in most reports. However, the
type of therapy used to treat hypertension could have
contributed these inconsistencies in the results obtained.
Overall, the effect that the type of antihypertensive treatment
may have on cognitive function has been assessed in over
58 clinical studies. More than 8000 patients on diuretics
have been investigated in 13 studies; most of them were
receiving thiazide diuretics (Solomon et al 1983; Lasser et
al 1989; Schmidt et al 1989; Bird et al 1990; Goldstein et al
1990; Cushman et al 1991; Nikolaus et al 2000; Ogihara
and Kuramoto 2000). In most studies, diuretics were
administered in combination with other drugs, whereas few
studies analyzed the effect of diuretics as monotherapy. In
general, these studies seem to indicate that diuretics neither
improve nor aggravate cognitive function. Beta-blockers
were investigated in 19 studies involving 13 000 subjects.
No changes in cognitive function seem to take place with
this type of therapy, although some worsening has been
reported with propranolol and slight improvements were
seen with beta 1-selective blocking agents. However, it is
generally accepted that these drugs do not have a positive
effect on cognitive function (Madden et al 1986, 1988;
Steufert et al 1988; Palac et al 1990; Steiner et al 1990).
ACE inhibitors have been evaluated in 9 studies including
a population of somewhat over 9000 hypertensive patients.
A positive influence on cognitive function was observed in
these studies, especially on cognitive function impairmentVascular Health and Risk Management 2006:2(4) 496
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of vascular etiology, which was more favorable that the
effect obtained with diuretics and beta-blockers (Ameiling
et al 1991; Frimodt-Moeller et al 1991).
The effect of calcium channel antagonists have been
analyzed in 13 studies involving a population of
approximately 10 000 hypertensive patients. The drug
classes investigated were dihydropyridine calcium channel
antagonists and, to a lesser extent, verapamil
 and diltiazem
(Scarzella et al 1989; Leonetti and Salvetti 1994; Maxwell
et al 1996; Palmer et al 1990; Ogihara et al 1992; Bulpitt et
al 2000). Most data on dihydropyridines (nitrendipine) were
obtained in the Syst-Eur study (Forette et al 1998). It has
been generally shown that calcium channel antagonists
improve cognitive function and reduce the incidence of
vascular dementia. However, nifedipine compared with
atenolol may subtly impair learning and memory in some
elderly hypertensive patients (Skinner et al 1992).
Improvement of cognitive function obtained with calcium
channel antagonists seems to be similar or even higher than
with other antihypertensive agents (Staessen et al 1998;
Forette et al 2002). These drugs may prevent the onset of
dementia not only in hypertensive subjects, but also in
normotensive individuals (Maxwell et al 1996).
Studies on angiotensin-II receptor antagonists with
losartan and valsartan have shown an improvement in
cognitive function with the use of these antihypertensive
drugs (Soma et al 1998; Tedesco et al 1999; Fogari et al
2003, 2004). No improvement was observed with
candesartan in the recently published SCOPE study (Lithell
et al 2003). The SCOPE study involved over 5000
hypertensive patients older than 70 years whose cognitive
function was evaluated using the MMSE. Subjects were
randomized to either candesartan or placebo, with the
possibility of openly receiving other antihypertensive agents
(excluding angiotensin-II receptor antagonists) to achieve
adequate BP control. This caused 84% of the patients in the
control group to receive treatment as well, whereas only
25% of the patients in the candesartan group took the drug
as monotherapy, so it became very difficult to individualize
the outcomes by treatment arm. This study did not shown
improvement or aggravation of cognitive function. In our
study, in which 98% of the patients were treated with
lercanidipine and only 20% received additional therapy with
an ACE inhibitor or doxazosin, a statistically significant
improvement of cognitive function in the TMT scores after
6 months of treatment was observed. This finding is
clinically relevant, not only because of improvement of
cognitive function itself, but also because improvement has
occurred after 6 months of treatment, whereas hypertension-
related abnormalities that may lead to dementia are observed
many years later. Lercanidipine is a highly lipophilic third-
generation dihydropyridine calcium channel antagonist that
is characterized by its vascular selectivity. The action of
lercanidipine is much longer than other calcium channel
antagonists, and its antihypertensive efficacy and tolerability
have been documented in over 16 000 hypertensive patients.
The favorable tolerability profile of this drug has been
extensively documented in daily practice. The potential
antiatherogenic effects of lercanidipine could explain the
improvement of cognitive function especially of the vascular
type. However, the role that BP reduction or the
antiatherogenic effect of lercanidipine may play on cognitive
function improvement is merely speculative and has not
been investigated here. Lercanidipine is an alternative
antihypertensive medication that can be seriously considered
for the management of hypertensive patients with cognitive
dysfunction, and it should be preferred to other
dihydropyridine calcium channel antagonists that have been
also shown to have beneficial effects on cognitive function.
In summary, lercanidipine was an efficient drug for
achieving BP control in 68% of hypertensive patients who
were previously uncontrolled or initiated antihypertensive
pharmacological treatment. The safety profile of the drug
was good, as shown by 98% of the patients still receiving
lercanidipine treatment at the end of the study. Lercanidipine
improved cognitive function after 6 months of treatment as
measured using the MMSE. This improvement was even
more remarkable in patients with adequate BP control,
suggesting that better cognitive function may be associated
with a reduction in BP.
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